This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Unigene's Oral PTH Phase 2 Proof-of-Concept Data To Be Presented At Upcoming Scientific Conferences













BOONTON, N.J., June 28, 2012 /PRNewswire/ --  Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that data from the Company's oral parathyroid hormone (PTH) analog Phase 2 proof-of-concept trial results will be part of two presentations by Dr. Lorraine Fitzpatrick, Medicine Development Leader for GlaxoSmithKline (GSK), at prestigious scientific conferences. 

5th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease

"(Mis)Adventures In Drug Discovery"

  • Date & Time: Thursday, June 28, 2012 at 11:30 a.m. GMT
  • Location:  St. Catherine's College, Oxford, UK
  • Focus: Examination of PTH secretory dynamics via the comparison of PK data from ronacaleret, oral PTH, and PTH 1-34 and 1-84 




GIOSEG 5th Meeting Skeletal Endocrinology

SESSION 4 - Anabolic Therapies for Osteoporosis – "New PTHs: Modalities, Duration, Combinations"

  • Date & Time: Friday, September 21, 2012 from 2:30 - 4:00 p.m. BST
  • Location: University of Brescia, Main Hall School of Medicine, Brescia, Italy
  • Focus: Examination of PTH secretory dynamics via the comparison of PK data from ronacaleret, oral PTH, and PTH 1-34 and 1-84

"We are extremely pleased Dr. Fitzpatrick has chosen to present the data from our oral PTH Phase 2 proof-of-concept trial at two highly prestigious scientific conferences," stated Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene.  "Both presentations will serve to highlight data that strongly validate Unigene's proprietary Peptelligenceâ„¢ technology and, importantly, that the oral delivery of PTH is technically feasible."

The Phase 2 proof-of-concept oral PTH study was conducted by Unigene under a now terminated, amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GSK pertaining to an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs